Research Article
Clinical Evaluation and Cost-Effectiveness Analysis of Serum Tumor Markers in Lung Cancer
Table 5
Cost-effectiveness analysis of different combinations of tumor markers at the current cost and with a 10% decrease in cost.
| | Group | Cost (C)/¥ | Effectiveness (E)/% | | |
| | SCCA + NSE | 177 (159.3) | 56.82 | 3.12 (2.80) | 0.00 (0.00) | | SCCA + CEA | 177 (159.3) | 60.61 | 2.92 (2.63) | 0.00 (0.00) | | NSE + CEA | 200 (180) | 67.42 | 2.97 (2.67) | 2.17 (1.95) | | NSE + CYFRA21-1 | 200 (180) | 64.39 | 3.11 (2.80) | 3.04 (2.73) | | CEA + CYFRA21-1 | 200 (180) | 64.39 | 3.11 (2.80) | 3.04 (2.73) | | SCCA + NSE + CEA | 277 (249.3) | 70.45 | 3.93 (3.54) | 7.34 (6.60) | | SCCA + NSE + CYFRA21-1 | 277 (249.3) | 65.15 | 4.25 (3.83) | 12.00 (10.80) | | SCCA + CEA + CYFRA21-1 | 277 (249.3) | 70.45 | 3.93 (3.54) | 7.34 (6.60) | | NSE + CEA + CYFRA21-1 | 300 (270) | 75.76 | 3.96 (3.56) | 6.49 (5.84) | | SCCA + NSE + CEA + CYFRA21-1 | 377 (339.3) | 78.03 | 4.83 (4.35) | 9.43 (8.49) |
|
|
